Cargando…

Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19

Herein, the preparation of the key triazone-triazole intermediate of ensitrelvir (S-217622) via sequential cyclization and alkylation reaction is described. Firstly, chloromethyl triazole was synthesized through a one-pot tandem process (condensation and cyclization reaction) from commercially avail...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Wei, Zhang, Xiang, Liu, Yuanchang, Liu, Teng, Wen, Jiale, Peng, Xiaopeng, Xie, Xin, Chen, Weiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724693/
https://www.ncbi.nlm.nih.gov/pubmed/36540243
http://dx.doi.org/10.1039/d2ra06841a
_version_ 1784844469568274432
author Hu, Wei
Zhang, Xiang
Liu, Yuanchang
Liu, Teng
Wen, Jiale
Peng, Xiaopeng
Xie, Xin
Chen, Weiming
author_facet Hu, Wei
Zhang, Xiang
Liu, Yuanchang
Liu, Teng
Wen, Jiale
Peng, Xiaopeng
Xie, Xin
Chen, Weiming
author_sort Hu, Wei
collection PubMed
description Herein, the preparation of the key triazone-triazole intermediate of ensitrelvir (S-217622) via sequential cyclization and alkylation reaction is described. Firstly, chloromethyl triazole was synthesized through a one-pot tandem process (condensation and cyclization reaction) from commercially available chloroacetamide in a 72% yield. Then, the key triazone-triazole intermediate was obtained in a second one-pot process by N-alkylation with triazone followed by highly selective N(1)-methylation with iodomethane in a 54% yield. In addition, two of the main process impurities were synthesized and identified. This novel alternative two-stage one-pot strategy for synthesizing the key triazone-triazole intermediate opens a new avenue for further research and development of ensitrelvir analogs.
format Online
Article
Text
id pubmed-9724693
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Royal Society of Chemistry
record_format MEDLINE/PubMed
spelling pubmed-97246932022-12-19 Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19 Hu, Wei Zhang, Xiang Liu, Yuanchang Liu, Teng Wen, Jiale Peng, Xiaopeng Xie, Xin Chen, Weiming RSC Adv Chemistry Herein, the preparation of the key triazone-triazole intermediate of ensitrelvir (S-217622) via sequential cyclization and alkylation reaction is described. Firstly, chloromethyl triazole was synthesized through a one-pot tandem process (condensation and cyclization reaction) from commercially available chloroacetamide in a 72% yield. Then, the key triazone-triazole intermediate was obtained in a second one-pot process by N-alkylation with triazone followed by highly selective N(1)-methylation with iodomethane in a 54% yield. In addition, two of the main process impurities were synthesized and identified. This novel alternative two-stage one-pot strategy for synthesizing the key triazone-triazole intermediate opens a new avenue for further research and development of ensitrelvir analogs. The Royal Society of Chemistry 2022-12-06 /pmc/articles/PMC9724693/ /pubmed/36540243 http://dx.doi.org/10.1039/d2ra06841a Text en This journal is © The Royal Society of Chemistry https://creativecommons.org/licenses/by-nc/3.0/
spellingShingle Chemistry
Hu, Wei
Zhang, Xiang
Liu, Yuanchang
Liu, Teng
Wen, Jiale
Peng, Xiaopeng
Xie, Xin
Chen, Weiming
Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19
title Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19
title_full Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19
title_fullStr Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19
title_full_unstemmed Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19
title_short Two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (S-217622), an oral clinical candidate for treating COVID-19
title_sort two-stage one-pot synthetic strategy for the key triazone-triazole intermediate of ensitrelvir (s-217622), an oral clinical candidate for treating covid-19
topic Chemistry
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9724693/
https://www.ncbi.nlm.nih.gov/pubmed/36540243
http://dx.doi.org/10.1039/d2ra06841a
work_keys_str_mv AT huwei twostageonepotsyntheticstrategyforthekeytriazonetriazoleintermediateofensitrelvirs217622anoralclinicalcandidatefortreatingcovid19
AT zhangxiang twostageonepotsyntheticstrategyforthekeytriazonetriazoleintermediateofensitrelvirs217622anoralclinicalcandidatefortreatingcovid19
AT liuyuanchang twostageonepotsyntheticstrategyforthekeytriazonetriazoleintermediateofensitrelvirs217622anoralclinicalcandidatefortreatingcovid19
AT liuteng twostageonepotsyntheticstrategyforthekeytriazonetriazoleintermediateofensitrelvirs217622anoralclinicalcandidatefortreatingcovid19
AT wenjiale twostageonepotsyntheticstrategyforthekeytriazonetriazoleintermediateofensitrelvirs217622anoralclinicalcandidatefortreatingcovid19
AT pengxiaopeng twostageonepotsyntheticstrategyforthekeytriazonetriazoleintermediateofensitrelvirs217622anoralclinicalcandidatefortreatingcovid19
AT xiexin twostageonepotsyntheticstrategyforthekeytriazonetriazoleintermediateofensitrelvirs217622anoralclinicalcandidatefortreatingcovid19
AT chenweiming twostageonepotsyntheticstrategyforthekeytriazonetriazoleintermediateofensitrelvirs217622anoralclinicalcandidatefortreatingcovid19